In order to complete such analysis, the complement deficiency at RTX-chemotherapy initiation was based on observing C3c and C4, as well as the cytogenetic status and FcγR3A V158F polymorphism known to be critical for proper CDC and ADCC, respectively (Table 3). Here, C4A is linked to complement deficiency.